Microcap March Madness: LNAI, FAGI, VSA, LNKS Sweet 16 Underdog WatchA new wave of activity across biotech innovation, artificial intelligence, digital infrastructure, and global manufacturing is drawing increased investor attention as several emerging growth companies report significant developments that could shape their next phase of expansion.
$400M to $1.2 Billion US Countermeasures Program Presents Huge Opportunity for New AI Platform to Meet Emerging Battlefield and Terrorism Threats: Lunai Bioworks (Nasdaq: LNAI)Lunai Bioworks (Nasdaq: LNAI ) is an AI-enabled biotechnology company advancing rapid in vivo phenotypic drug discovery across CNS and biodefense applications. By integrating high-throughput vertebrate screening with machine learning analytics, LNAI seeks to accelerate therapeutic discovery while reducing cost, time, and capital intensity.
Full Alliance (OTCQB: FAGI) Aquaox Pure Solutions’ JusSpray™ Surges on Amazon DemandFull Alliance Group (OTCQB: FAGI) continues executing its multi-vertical growth strategy as its subsidiary Aquaox Pure Solutions, LLC reports accelerating marketplace traction for JusSpray™, the company’s flagship hypochlorous acid (HOCl) skin defense spray.
Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic CompoundsNEW YORK, NY / ACCESS Newswire / October 30, 2025 / In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. (
NASDAQ:LNAI) today announced promising early results from its AI-based platform designed to identify compounds that interact with acetylcholinesterase (AChE), the same molecular target affected by nerve agents.
Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum ProteomicsPublished in Nature Communications, a new study uncovers critical protein biomarkers that predict functional decline in Duchenne Muscular Dystrophy (DMD), opening doors to more personalized care and improved clinical trials.
Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price RequirementLOS ANGELES, CALIFORNIA / ACCESS Newswire / October 16, 2025 / Lunai Bioworks, Inc. (Nasdaq:LNAI), today announced that it has regained compliance with Nasdaq's minimum bid price requirement.
Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative PipelineLOS ANGELES, CALIFORNIA / ACCESS Newswire / October 6, 2025 / Lunai Bioworks (Nasdaq:LNAI) today announced a major advance in Alzheimer's research: its AI platform, Augusta™, achieved up to a 35% improvement in diagnostic accuracy by combining MRI scans with genetic and metabolic data. The company is launching a preclinical Alzheimer's program to bring this technology closer to clinical use, a move that could enable earlier intervention for millions worldwide.
